Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on July 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E Lowenthal, the President and CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on July 9, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• 50,000 shares were sold at a weighted average price of $9.6177, with prices ranging from $9.38 to $9.81.
• The other 50,000 shares were sold at a weighted average price of $9.6168, with prices ranging from $9.38 to $9.805.
• Following the transactions, Lowenthal directly owns 4,315,313 shares.
• Lowenthal also has indirect ownership through various trusts, including the Richard Lowenthal Charitable Remainder UniTrust (1,496,494 shares), the Lowenthal-Tanimoto Family Trust (1,648,499 shares), and the Sarina Tanimoto Charitable Remainder UniTrust (1,597,447 shares).
• His spouse also holds 3,407,847 shares.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Executive share sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-arranged. However, investors often monitor insider transactions for signals about a company's prospects.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sale, although the impact is likely to be limited due to the pre-arranged nature of the transactions.
• The sales do not directly impact employees, customers, suppliers, or creditors.

Key Dates